BioNTech pays $205M for FDA voucher to speed up 'late-stage oncology pipeline'

BioNTech has purchased an FDA priority review voucher from Scholar Rock for $205 million to accelerate the FDA review timeline of a future drug filing in its late-stage oncology pipeline, most likely the PD-L1xVEGF bispecific pumitamig. The voucher shortens FDA approval from 10 to 6 months, potentially speeding up market entry for the drug.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 10 Nov 2026 and 12 Nov 2026.